Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...